5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.17▲ | 3.15▲ | 3.16▲ | 3.64▼ | 3.75▼ |
MA10 | 3.18▲ | 3.16▲ | 3.28▼ | 3.78▼ | 4.36▼ |
MA20 | 3.17▲ | 3.30▼ | 3.48▼ | 3.94▼ | 4.19▼ |
MA50 | 3.15▲ | 3.58▼ | 3.77▼ | 4.87▼ | 4.15▼ |
MA100 | 3.27▼ | 3.77▼ | 3.86▼ | 4.02▼ | 12.88▼ |
MA200 | 3.46▼ | 3.88▼ | 4.32▼ | 3.00▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.004▲ | -0.028▼ | -0.032▼ | -0.062▼ |
RSI | 53.804▲ | 26.447▼ | 25.087▼ | 28.033▼ | 41.618▼ |
STOCH | 44.471 | 21.648 | 9.916▼ | 34.433 | 7.918▼ |
WILL %R | -35.713 | -79.518▼ | -87.218▼ | -92.166▼ | -97.964▼ |
CCI | -20.611 | -38.645 | -76.977 | -256.924▼ | -131.403▼ |
Monday, January 13, 2025 02:00 AM
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price ...
|
Friday, January 10, 2025 01:04 PM
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares ...
|
Friday, January 10, 2025 08:07 AM
(RTTNews) - Amylyx Pharmaceuticals, Inc. (AMLX), a Massachusetts-based biopharmaceutical ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/01/25 | 3.48 | 3.48 | 3.095 | 3.18 | 1,364,544 |
10/01/25 | 3.72 | 3.79 | 3.44 | 3.50 | 1,618,089 |
08/01/25 | 3.85 | 3.85 | 3.6505 | 3.77 | 289,522 |
07/01/25 | 3.96 | 3.975 | 3.79 | 3.85 | 362,798 |
06/01/25 | 4.10 | 4.17 | 3.91 | 3.92 | 489,575 |
03/01/25 | 3.99 | 4.18 | 3.925 | 4.15 | 440,494 |
02/01/25 | 3.79 | 4.045 | 3.77 | 3.91 | 527,893 |
31/12/24 | 3.86 | 3.9499 | 3.71 | 3.78 | 690,931 |
30/12/24 | 3.83 | 3.92 | 3.73 | 3.84 | 562,580 |
27/12/24 | 4.01 | 4.08 | 3.755 | 3.87 | 680,335 |
|
|
||||
|
|
||||
|
|